Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Angioedemas, Hereditary, Date of authorisation: 30/04/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Angioedemas, Hereditary, Date of authorisation: 30/04/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Semglee, insulin glargine, Diabetes Mellitus, Date of authorisation: 23/03/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Semglee, insulin glargine, Diabetes Mellitus, Date of authorisation: 23/03/2018, Revision: 10, Status: Authorised

Product Lifecycle Management (PLM) Value Stream Deep-Dive Webinar, Online 14:00 - 16:00 Amsterdam time (CEST), from 30/11/2023 to 30/11/2023

Product Lifecycle Management (PLM) Value Stream Deep-Dive Webinar, Online 14:00 - 16:00 Amsterdam time (CEST), from 30/11/2023 to 30/11/2023

Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Kirsty (previously Kixelle), insulin aspart, Diabetes Mellitus, Date of authorisation: 05/02/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Kirsty (previously Kixelle), insulin aspart, Diabetes Mellitus, Date of authorisation: 05/02/2021, Revision: 4, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness